Podium to Practice: ESMO® 2026 – LUNG: MDT-BRIDGE
OR
Studies / Trials Discussed
LBA62 – ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE
Chair
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Amgen.
Studies/trials discussed:
LBA62 – ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.